Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

被引:42
作者
Silver, H [1 ]
机构
[1] Technion Israel Inst Technol, Shaar Menashe Mental Hlth Ctr, Rappaport Fac Med, Mobile Post Hefer, IL-38814 Haifa, Israel
关键词
drug-drug interactions; fluvoxamine; negative symptoms; pharmacokinetics; schizophrenia; SSRI;
D O I
10.1097/00004850-200311000-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The treatment of negative symptoms of schizophrenia presents a major clinical challenge. This review examines the evidence pertaining to the efficacy, tolerability and safety of adding selective serotonin reuptake inhibitors (SSRIs) to antipsychotic agents in the treatment of negative symptoms in schizophrenia. Important methodological issues such as differentiating primary and secondary negative symptoms are discussed. The balance of available evidence indicates that at least some SSRIs, fluvoxamine and fluoxetine, can ameliorate primary negative symptoms in chronic schizophrenia patients who are treated with typical antipsychotics. The combination is safe and well tolerated although, as antipsychotic drug concentrations may be elevated, attention to dose and drug monitoring should be considered as appropriate. The effect of SSRI augmentation of atypical antipsychotics requires further study. Combination with clozapine may require particular caution because of potential toxicity if serum clozapine levels rise steeply. SSRI augmentation may be a useful addition to the treatment of schizophrenia. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:305 / 313
页数:9
相关论文
共 103 条
[31]   Negative symptoms in stroke patients and length of hospital stay [J].
Galynker, I ;
Prikhojan, A ;
Phillips, E ;
Focseneanu, M ;
Ieronimo, C ;
Rosenthal, R .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1997, 185 (10) :616-621
[32]  
Galynker II, 2000, NEUROPSY NEUROPSY BE, V13, P171
[33]   Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum [J].
Garver, DL ;
Holcomb, JA ;
Christensen, JD .
JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (12) :964-972
[34]   A PLACEBO-CONTROLLED TRIAL OF FLUOXETINE ADDED TO NEUROLEPTIC IN PATIENTS WITH SCHIZOPHRENIA [J].
GOFF, DC ;
MIDHA, KK ;
SARIDSEGAL, O ;
HUBBARD, JW ;
AMICO, E .
PSYCHOPHARMACOLOGY, 1995, 117 (04) :417-423
[35]   CLASSIFICATION OF DEPRESSIVE ILLNESSES [J].
HAMILTON, M .
BRITISH JOURNAL OF PSYCHIATRY, 1970, 117 (538) :348-+
[36]   BRIEF NEUROLEPTIC DISCONTINUATION AND CLINICAL SYMPTOMS IN KRAEPELINIAN AND NON-KRAEPELINIAN CHRONIC-SCHIZOPHRENIC PATIENTS [J].
HARVEY, PD ;
PUTNAM, KM ;
DAVIDSON, M ;
KAHN, RS ;
POWCHIK, P ;
MCQUEENEY, R ;
KEEFE, RSE ;
DAVIS, KL .
PSYCHIATRY RESEARCH, 1991, 38 (03) :285-292
[37]   Psychomotor slowing, negative symptoms and dopamine receptor availability - an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients [J].
Heinz, A ;
Knable, MB ;
Coppola, R ;
Gorey, JG ;
Jones, DW ;
Lee, KS ;
Weinberger, DR .
SCHIZOPHRENIA RESEARCH, 1998, 31 (01) :19-26
[38]   Longitudinal assessment of negative symptoms in schizophrenia/schizoaffective patients, other psychotic patients, and depressed patients [J].
Herbener, ES ;
Harrow, M .
SCHIZOPHRENIA BULLETIN, 2001, 27 (03) :527-537
[39]   NEUROCHEMICAL EFFECTS OF CHRONIC HALOPERIDOL AND LITHIUM ASSESSED BY BRAIN MICRODIALYSIS IN RATS [J].
HERNANDEZ, L ;
BAPTISTA, T ;
HOEBEL, BG .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1990, 14 :S17-S35
[40]   Fluvoxamine augmentation of olanzapine in chronic schizophrenia:: Pharmacokinetic interactions and clinical effects [J].
Hiemke, C ;
Jabarin, M ;
Hadjez, J ;
Weigmann, H ;
Härter, S ;
Modai, I ;
Ritsner, M ;
Silver, H .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (05) :502-506